Elicio Therapeutics, Inc. (ELTX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on March 5, 2025, by Elicio Therapeutics, Inc., a Delaware corporation. The report details the conversion of a senior secured convertible promissory note into common stock, an event that occurred on March 3, 2025, with share issuance finalized on March 5, 2025.
Key Financial Metrics and Capital Structure
- Debt Reduction: The Company satisfied a $20.0 million principal Convertible Note issued on August 12, 2024, to GKCC, LLC (an entity controlled by a board member).
- Equity Issuance: The Company issued 3,500,573 shares of Common Stock to the Purchaser in full satisfaction of the note, including all accrued and unpaid interest.
- Outstanding Shares: Following the issuance, there were 15,861,913 shares of Common Stock outstanding.
- Conversion Trigger: The conversion was triggered because the closing price of the Common Stock equaled or exceeded 135% of the initial conversion price of $5.81 for 20 trading days within a 30-day period.
Material Changes
The primary material change is the elimination of the $20.0 million Convertible Note liability and the corresponding increase in outstanding common stock. The filing does not provide specific values for accrued interest or the total conversion value beyond the share count.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the transaction. The transaction was executed pursuant to the exemption from registration under Section 3(a)(9) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact amount of accrued interest included in the 3,500,573 shares issued.
- Confirm the current trading price of ELTX relative to the $5.81 conversion price to understand the dilution impact.
- Review the updated capitalization table to assess the ownership percentage of GKCC, LLC post-conversion.
- Check for any subsequent filings regarding the use of proceeds or changes in the Company's liquidity position.